Table 1:

Strains used to assess human complement serum bactericidal activity of a serogroup B meningococcal vaccine and description of vaccine target antigens

Strain	ST	CC	PorA (VR2)	fHbp			NadA			NHBA
				Novartis variant*	Expression†	GenBank accession no.‡	Variant	Expression†	GenBank accession no.‡	Peptide	Expression†	GenBank accession no.‡
44/76-SL	32	32	16	1.1§	++	AY548370	x	x	x	3	+	AF226436
5/99	1349	8	2	2.2	−	GQ302858	2§	++	GQ302859	20	+/−	GQ302856
NZ98/254	42	41/44	4§	1.1	+	AY548375		x	x	2	+	GQ302855
M10713	136	41/44	16-3	2.2	+	NA	x	x	x	10§	+	NA
M00-242922	41	41/44	4§	1.4	+	FJ750977	x	x	x	2	+	FJ750982
M01-240101	1049	269	15	1.2	+	FJ750976	x	x	x	21	+/−	FJ750981
M01-240355	213	213	14	3.3	+/−	EU541888	5	+/−	FJ750979	18	+/−	GQ302857
M01-240364	11	11	2	3.3	+/−	FJ750978	2§	+	FJ619643	28	+/−	FJ750980

Note: CC = clonal complex, fHbp = factor H binding protein, NadA = Neisseria adhesin A, NA = GenBank accession number not assigned, NHBA = Neisseria heparin binding antigen, PorA = porin A, ST = sequence type, VR2 = variable region 2, x = does not harbour the NadA gene.

^*The fHbp variant nomenclature displayed is the one used by Novartis obtained by adding a prefix defining the main variant (1, 2 or 3) to the subvariant.¹⁰

^†Expression of antigen as determined by binding of murine antibodies raised against each of the vaccine antigen(s): − low expression, +/− medium expression, + high expression, ++ very high expression.

^‡GenBank accession number identifying unique sequence at www.ncbi.nlm.nih.gov.

^§These vaccine targets are homologous (PorA, fHbp, NHBA) or cross-reactive (NadA) to those contained in 4CMenB.